Subcutaneous infusion of levodopa-carbidopa beneficial for Parkinson’s disease

Subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) increases on time without troublesome dyskinesia among patients with Parkinson disease, according to a study published online March 15 in The Lancet Neurology.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup